|The BORRELIA BURGDORFERI OUTER SURFACE PROTEIN B P19 ospb (Catalog #MBS211486) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. MyBioSource\'s BORRELIA BURGDORFERI OUTER SURFACE PROTEIN B P19 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA). Researchers should empirically determine the suitability of the BORRELIA BURGDORFERI OUTER SURFACE PROTEIN B P19 ospb for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The BORRELIA BURGDORFERI OUTER SURFACE PROTEIN B P19 ospb product has the following accession number(s) (GI #730239) (NCBI Accession #Q09090.1). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
MBS211486 reacts specifically with Osp B, p19 from Borrelia burgdorferi, the causative agent of Lyme disease.
Perservative Stabilisers: 0.09% Sodium Azide (NaN3)
Preparation: Purified IgG prepared by affinity chromatography on Protein A. Immunogen: Native, Borrelia lysate
Buffer Solution: Phosphate buffered saline
Target Species: Bacterial. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing BORRELIA BURGDORFERI OUTER SURFACE PROTEIN B P19 are readily searchable from our website. Different antibodies against the same target such as BORRELIA BURGDORFERI OUTER SURFACE PROTEIN B P19 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.